# Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia

Study · id `cardio:ct-nct07485283` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07485283](<https://clinicaltrials.gov/study/NCT07485283>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07485283

Browse, organ or system: Heart; Brain  
Browse, condition area: Coronary and vascular disease; Stroke; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 168460 participants.

## Technical summary

Registry record NCT07485283. Randomized; no masking; primary purpose prevention. Start 2026-04-28 (actual); primary completion 2029-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 168460 participants (enrolled count; ClinicalTrials.gov record NCT07485283, source copy `cardio:ctgov-nct07485283-2026-10-14`, retrieved 2026-10-26)
- Started: 2026-04-28 (actual) (ClinicalTrials.gov record NCT07485283, source copy `cardio:ctgov-nct07485283-2026-10-14`, retrieved 2026-10-26)
- Primary completion: 2029-06 (anticipated) (ClinicalTrials.gov record NCT07485283, source copy `cardio:ctgov-nct07485283-2026-10-14`, retrieved 2026-10-26)
- Completion: 2029-06 (anticipated) (ClinicalTrials.gov record NCT07485283, source copy `cardio:ctgov-nct07485283-2026-10-14`, retrieved 2026-10-26)
- Countries: Denmark (ClinicalTrials.gov record NCT07485283, source copy `cardio:ctgov-nct07485283-2026-10-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07485283-2026-10-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia
- Acronym: DAN-ZOSTER
- Condition: Cardiovascular Disease
- Condition: Dementia
- Intervention (Biological): Recombinant Herpes Zoster Vaccine (Shingrix)
- Lead sponsor: Tor Biering-Sørensen
- Lead sponsor class: OTHER
- Collaborator: GlaxoSmithKline
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Tor Biering-Sørensen (`cardio:org-tor-biering-srensen-bf541f`)
- Registry lists this organization as a collaborator: GlaxoSmithKline (`cardio:org-glaxosmithkline`)

## Provenance

Content hash: 4ebc27494e64407ebeaa60b8fe970018383dd2ee3ed1481fe04edac178404c4f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
